Prevalent new user designs: A literature review of current implementation practice
- PMID: 37309989
- DOI: 10.1002/pds.5656
Prevalent new user designs: A literature review of current implementation practice
Abstract
Purpose: Prevalent new user (PNU) designs extend the active comparator new user design by allowing for the inclusion of initiators of the study drug who were previously on a comparator treatment. We performed a literature review summarising current practice.
Methods: PubMed was searched for studies applying the PNU design since its proposal in 2017. The review focused on three components. First, we extracted information on the overall study design, including the database used. We summarised information on implementation of the PNU design, including key decisions relating to exposure set definition and estimation of time-conditional propensity scores. Finally, we reviewed the analysis strategy of the matched cohort.
Results: Nineteen studies met the criteria for inclusion. Most studies (73%) implemented the PNU design in electronic health record or registry databases, with the remaining using insurance claims databases. Of 15 studies including a class of prevalent users, 40% deviated from the original exposure set definition proposals in favour of a more complex definition. Four studies did not include prevalent new users but used other aspects of the PNU framework. Several studies lacked details on exposure set definition (n = 2), time-conditional propensity score model (n = 2) or integration of complex analytical techniques, such as the high-dimensional propensity score algorithm (n = 3).
Conclusion: PNU designs have been applied in a range of therapeutic and disease areas. However, to encourage more widespread use of this design and help shape best practice, there is a need for improved accessibility, specifically through the provision of analytical code alongside guidance to support implementation and transparent reporting.
Keywords: database research; literature review; prevalent new user designs.
© 2023 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221-228. doi:10.1007/s40471-015-0053-5
-
- Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920. doi:10.1093/aje/kwg231
-
- Suissa S, Moodie EEM, Dell'Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf. 2017;26(4):459-468. doi:10.1002/pds.4107
-
- Lin HMD, Lai CL, Dong YH, Tu YK, Chan KA, Suissa S. Re-evaluating safety and effectiveness of dabigatran versus warfarin in a Nationwide data environment: a prevalent new-user design study. Drugs-Real World Outcomes. 2019;6(3):93-104. doi:10.1007/s40801-019-0156-2
-
- Webster-Clark M, Ross RK, Lund JL. Initiator types and the causal question of the prevalent new-user design: a simulation study. Am J Epidemiol. 2021;190(7):1341-1348. doi:10.1093/aje/kwaa283
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
